The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
|Videos|June 15, 2011
Dr. Chapman Describes Recent Melanoma Advances
Author(s)Paul Chapman, MD
Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances
Advertisement
Paul Chapman, MD, From Memorial Sloan-Kettering Cancer Center describes recent melanoma advances.
Dr. Chapman says there are now two drugs that improve survival in patients with metastatic melanoma. He adds that this has never happened before in melanoma because only two years ago there was no drug that was shown to improve survival in patients. He says physicians now have choices. While the drugs still need to be improved, they are a start and something that can be built upon in terms of combination therapies.
Advertisement
Related to this article
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5